Bilkent University National Nanotechnology Research Center’s (UNAM) Dr. Gurkan Yesiloz and his team have developed an innovative nano-bioconjugate drug delivery system designed to treat various diseases. This research seeks to improve the effectiveness of current treatment methods, particularly for cancer, while reducing side effects.
The technology, built on protein-based nano-carrier systems, ensures the controlled and targeted delivery of drugs within the body, making it compatible with both hydrophilic and hydrophobic compounds. By protecting healthy cells and delivering drugs directly to diseased cells, it offers effective treatment at significantly lower doses, greatly reducing the risk of toxicity.
Having successfully passed laboratory tests and currently in the patent process, the technology developed by Dr. Yesiloz and his team holds significant potential for the healthcare and pharmaceutical industries. The team is rapidly progressing in their efforts to transform this innovative system into a commercial product and introduce it to the healthcare sector, and they have recently been recognized by TÜBİTAK’s Individual Young Enterprise (BİGG) program and awarded the “Seal of Excellence” for their work.
